Among the NRF2 targets involved in chemotherapeutic resistance, there is catalase, whose overexpression protects cancer cells from apoptosis induced by DNA-damaging agents [79,80] and NQO1, whose inhibition potentiates the cytotoxicity of anticancer treatments [81,82]. Here, NFE2L2 is linked to cancer.